School of Chemistry - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 3 of 3
  • Item
    Thumbnail Image
    Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia
    Laurens, E ; Yeoh, SD ; Rigopoulos, A ; O'Keefe, GJ ; Tochon-Danguy, HJ ; Chong, LW ; White, JM ; Scott, AM ; Ackermann, U (WILEY-BLACKWELL, 2016-08)
    The significance of imaging hypoxia with the positron emission tomography ligand [(18) F]FMISO has been demonstrated in a variety of cancers. However, the slow kinetics of [(18) F]FMISO require a 2-h delay between tracer administration and patient scanning. Labeled chloroethyl sulfoxides have shown faster kinetics and higher contrast than [(18) F]FMISO in a rat model of ischemic stroke. However, these nitrogen mustard analogues are unsuitable for routine production and use in humans. Here, we report on the synthesis and in vitro and in vivo evaluation of a novel sulfoxide, which contains an ester moiety for hydrolysis and subsequent trapping in hypoxic cells. Non-decay corrected yields of radioactivity were 1.18 ± 0.24% (n = 27, 2.5 ± 0.5% decay corrected radiochemical yield) based on K[(18) F]F. The radiotracer did not show any defluorination and did not undergo metabolism in an in vitro assay using S9 liver fractions. Imaging studies using an SK-RC-52 tumor model in BALB/c nude mice have revealed that [(18) F]1 is retained in hypoxic tumors and has similar hypoxia selectivity to [(18) F]FMISO. Because of a three times faster clearance rate than [(18) F]FMISO from normoxic tissue, [(18) F]1 has emerged as a promising new radiotracer for hypoxia imaging.
  • Item
    No Preview Available
    Rhenium and technetium tricarbonyl complexes of 1,4-substituted pyridyl-1,2,3-triazole bidentate ‘click’ ligands conjugated to a targeting RGD peptide
    Connell, TU ; Hayne, DJ ; Ackermann, U ; White, JM ; Donnelly, PS ; Tochon-Danguy, H (Wiley, 2014)
    New 1,4‐substituted pyridyl‐1,2,3‐triazole ligands with pendent phenyl isothiocyanate functional groups linked to the heterocycle through a short methylene or longer polyethylene glycol spacers were prepared and conjugated to a peptide containing the arginine–glycine–aspartic acid peptide motif. Rhenium and technetium carbonyl complexes, [M(CO)3Lx(py)]+ (where M = ReI or 99mTcI; Lx = 1,4‐substituted pyridyl‐1,2,3‐triazole ligands and py = pyridine) were prepared. One rhenium complex has been characterized by X‐ray crystallography, and the luminescent properties of [M(CO)3Lx(py)]+ are reported.
  • Item
    Thumbnail Image
    Rhenium and technetium complexes that bind to amyloid-β plaques
    Hayne, DJ ; North, AJ ; Fodero-Tavoletti, M ; White, JM ; Hung, LW ; Rigopoulos, A ; McLean, CA ; Adlard, PA ; Ackermann, U ; Tochon-Danguy, H ; Villemagne, VL ; Barnham, KJ ; Donnelly, PS (ROYAL SOC CHEMISTRY, 2015)
    Alzheimer's disease is associated with the presence of insoluble protein deposits in the brain called amyloid plaques. The major constituent of these deposits is aggregated amyloid-β peptide. Technetium-99m complexes that bind to amyloid-β plaques could provide important diagnostic information on amyloid-β plaque burden using Single Photon Emission Computed Tomography (SPECT). Tridentate ligands with a stilbene functional group were used to form complexes with the fac-[M(I)(CO)3](+) (M = Re or (99m)Tc) core. The rhenium carbonyl complexes with tridentate co-ligands that included a stilbene functional group and a dimethylamino substituent bound to amyloid-β present in human frontal cortex brain tissue from subjects with Alzheimer's disease. This chemistry was extended to make the analogous [(99m)Tc(I)(CO)3](+) complexes and the complexes were sufficiently stable in human serum. Whilst the lipophilicity (log D7.4) of the technetium complexes appeared ideally suited for penetration of the blood-brain barrier, preliminary biodistribution studies in an AD mouse model (APP/PS1) revealed relatively low brain uptake (0.24% ID g(-1) at 2 min post injection).